PCM
LAB icon

Palisade Capital Management’s Standard BioTools LAB Stock Holding History

Palisade Capital Management’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-17,755
Closed -$430K – 556
2015
Q2 		$430K Buy
+17,755
New +$560K 0.01% 481

Other funds holding LAB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
EverPoint Asset Management Stamford, Connecticut $5.38B AUM 21.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Palisade Capital Management's LAB Position: Q3 2015 in Review

Palisade Capital Management sold out of Standard BioTools (LAB) in Q3 2015, closing a stake of 17,755 shares — an estimated $430K sold.

Palisade Capital Management first reported a position in LAB in Q2 2015 and held it in 1 quarter. The position peaked at $430K in Q2 2015. 109 funds tracked by Wall St. Rank hold LAB as of Q3 2015.

  • Palisade Capital Management reported no remaining Standard BioTools position as of Q3 2015 after selling out during the quarter.
  • Palisade Capital Management sold 17,755 Standard BioTools shares in Q3 2015, an estimated $430K.
  • Palisade Capital Management first reported a position in Standard BioTools in Q2 2015 and held it in 1 quarter.
  • Palisade Capital Management's Standard BioTools position peaked at $430K in Q2 2015.
  • 109 funds tracked by Wall St. Rank held Standard BioTools as of Q3 2015.

Based on Palisade Capital Management's 13F filing for Q3 2015, filed 29 Oct 2015.